CIPLA LTD MD
Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar
Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for this drug is expected to expire around 2029, allowing for potential market entry. Cipla anticipates capturing a significant share of this lucrative market segment after the launch. Additionally, the company reported a 35% decline in consolidated net profit in the September quarter.
Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%
Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker North American sales. India revenue grew 12%, while US regulatory approval and a biosimilar partnership supported its product pipeline.
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%
Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-year decline in revenue from operations, totaling Rs 7,404 crore. Additionally, a significant 26.7% decrease in EBITDA resulted in a lower margin of 18.7%. Nonetheless, Cipla's One India division demonstrated growth across various segments, while the company aims to enhance productivity and innovate its product offerings.
Nifty 50 companies likely to log strong double-digit growth in Q2
Revenue and net profit of Nifty 50 companies are projected to grow by nearly 20% year-on-year. Analysts note that performance is driven by sectors like automobiles, banking, and oil. Operating margins, however, might contract slightly due to input cost pressures and inflation. Key sectors show varied conditions, balancing strong demand against potential challenges. Overall, medium to long-term outlook remains optimistic, despite some near-term volatility.
Cipla global CEO Umang Vohra to step down; Achin Gupta to take over
Cipla's global CEO Umang Vohra will step down in March 2026. Achin Gupta, currently global COO, will take over as the new MD and GCEO from April 1, 2026. Gupta joined Cipla in 2021 and has been instrumental in driving growth and strengthening operations. He holds degrees from IIT Delhi and IIM Ahmedabad.
Reports of likely promoter stake sale making people anxious: Cipla MD Vohra
"We're all human beings, we get distracted with what happens, because of this and that distraction creates difficulties for us in the way we engage with each other, and the way we engage with the organization. That, I believe, is the biggest impact of this uncertainty," Vohra added. Vohra said the promoters' and the company are two different entities.
- Go To Page 1

Cipla vows to crack diabetes segment with licensed branded portfolio
"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing director and global CEO of Cipla in an interview to ET.

Cipla board approves reappointment of Umang Vohra as MD & Global CEO for 5 years
The board of directors has considered and approved the re-appointment of Umang Vohra, Managing Director, designated as 'Managing Director and Global Chief Executive Officer' of the company, for a further period of five years w.e.f. April 1, 2021 to March 31, 2026, Cipla said in a regulatory filing.

Cipla launches generic remdesivir for coronavirus patients
The USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of coronavirus patients.

Cipla ties up with Roche to sell 2 cancer drugs in India
The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India.

Cipla bags Rs 1,100 crore order from South African government
Cipla Medpro, the SA subsidiary of the Indian firm, has bagged the order as part of the South African government's 2015-17 National ARV tender.

Cipla shares end nearly 4% higher post agreement with Serum Institute
Cipla's stock surged 3.23 per cent to settle at Rs 618.60 on the BSE. In intra-day, it climbed 4.13 per cent to Rs 624.

Cipla Ltd to market Serum Institute's paediatric vaccines in Europe
Cipla has launched multiple respiratory products in Europe this year, and launch of some key inhalers is expected in 2015.
Buy Cipla with target price of Rs 436: Sandeep Wagle
Cipla is a 'BUY' with a target of Rs 436 and a stop loss of Rs 414.
Sell Cipla with target price of Rs 402: Sandeep Wagle
Sell Cipla with stoploss of Rs 421 and for target of Rs 402.
Buy Cipla Ltd with target price of Rs 440: Sandeep Wagle
Cipla Ltd is a 'BUY' call with a target of Rs 440 and a stop loss of Rs 406.
Sell Cipla with a target of Rs 385: Sandeep Wagle
Cipla Ltd is a ‘sell’ call with a target of Rs 385 and a stop loss of Rs 408.
Buy Cipla with a target price of Rs 440: Sandeep Wagle
Cipla is a 'BUY' call with a target of Rs 440 and a stop loss of Rs 415.
Buy Cipla with a target of Rs 411: Sandeep Wagle
"Cipla is a buy call with a target of Rs 411 and a stop loss of Rs 390."
Buy Cipla with a price target of Rs 410: Sandeep Wagle
Buy Cipla with a stop loss of Rs 390 and look for a price target of Rs 410.
Buy Cipla with target of Rs 406: Sandeep Wagle
"Buy Cipla with a stop loss of Rs 384 and a target price of Rs 406".
Sell Cipla with a target of 348: Sandeep Wagle
Cipla Ltd is a ‘SELL’ call with a target of Rs 348 and a stop loss of Rs 372.
Sell Cipla with a target of 348: Sandeep Wagle
Cipla Ltd is a ‘SELL’ call with a target of Rs 348 and a stop loss of Rs 372.
Buy Cipla with a target of 372: Sandeep Wagle
Cipla Ltd is a ‘BUY’ call with a target of Rs 372 and a stop loss of Rs 358.
Buy Cipla with a target of 372: Sandeep Wagle
Cipla Ltd is a ‘BUY’ call with a target of Rs 372 and a stop loss of Rs 354.
Buy Cipla with a target of 342: Sandeep Wagle
Cipla Ltd is a ‘BUY’ call with a target of Rs 342 and a stop loss of Rs 330.
Sell Cipla with target of 310: Sandeep Wagle
Sell Cipla in the range of 322 to 325 with stop loss of 327.50 and a target of 310.
Roche sues Cipla over Valcyte patent breach
Swiss major Roche has moved the Bombay High Court (HC) against domestic major Cipla for allegedly infringing both the patent and trademark of its patented drug Valcyte in India.
Load More